GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to analyze data in the foundation's patient-driven, real-world CoMMpass study.

GNS said the four are cyclin dependent kinase 1 (CDK1; CDC2); maternal embryonic leucine zipper kinase (MELK); protein kinase, membrane associated tyrosine/threonine 1 (PKMYT1); and NIMA-related kinase 2 (NEK2). The company also said its analysis showed that targeting certain translation elongation factors and ribosomal genes may drive durable responses in MM. It presented its results at the American Society of Hematology (ASH) meeting in San Diego. ...